Search Within

Lorenzo Falchi

Formats
  1. Meeting Abstract (96)
  2. Journal Article (23)
  3. Research Letter (6)
  4. Review (5)
  5. Correspondence (2)
  6. Editorial (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (134)
  2. Hematologic Malignancies, Division of (134)
  3. Center for Hematologic Malignancies (88)
  4. Lymphoma (78)
  5. Sloan Kettering Institute Postdocs (57)
  6. Survivorship Research (54)

More Groups

People
  1. Gilles Salles (66)
  2. Andrew Zelenetz (64)
  3. Maria Palomba (63)
  4. Anita Kumar (61)
  5. Ariela Noy (57)
  6. Alison Moskowitz (54)

More People

Years
  1. 2025 (8)
  2. 2024 (40)
  3. 2023 (43)
  4. 2022 (23)
  5. 2021 (14)
  6. 2020 (6)
Publications
  1. Blood (67)
  2. Journal of Clinical Oncology (11)
  3. Hematological Oncology (9)
  4. Blood Advances (5)
  5. Clinical Lymphoma, Myeloma and Leukemia (5)
  6. Leukemia and Lymphoma (5)

More Publications

Publishers
  1. American Society of Hematology (72)
  2. American Society of Clinical Oncology (11)
  3. Wiley Blackwell (9)
  4. Elsevier Inc. (8)
  5. Taylor & Francis Group (5)
  6. Ferrata Storti Foundation (4)

More Publishers

Results (134)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • High complete metabolic response rates with epcoritamab + R‐CHOP in previously untreated (1L) high‐risk DLBCL, including double‐hit/triple‐hit: EPCORE NHL‐2 update
    Meeting Abstract

    Falchi, L.; Clausen, M. R.; Offner, F.; de Vos, S.; Brody, J.; Linton, K. M.; Snauwaert, S.; Cordoba, R.; Wu, J.; Bykhovski, I.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Glofitamab monotherapy in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL): Extended follow‐up and landmark analyses from a pivotal phase II study
    Meeting Abstract

    Dickinson, M.; Carlo‐Stella, C.; Morschhauser, F.; Falchi, L.; Bachy, E.; Cartron, G.; Khan, C.; Tani, M.; Martinez‐Lopez, J.; Bartlett, N.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Epcoritamab with rituximab + lenalidomide (R2) provides durable responses in high‐risk follicular lymphoma, regardless of POD24 status
    Meeting Abstract

    Belada, D.; Falchi, L.; Leppä, S.; Vermaat, J. S.; Holte, H.; Hutchings, M.; Lugtenburg, P.; de Vos, S.; Abrisqueta, P.; Nijland, M.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Small volume biopsy diagnostic yield at initial diagnosis versus recurrence/transformation of follicular lymphoma: A retrospective Cyto-Heme Interinstitutional Collaborative study
    Journal Article

    Fitzpatrick, M. J.; Sundaram, V.; Ly, A.; Abramson, J. S.; Balassanian, R.; Cheung, M. C.; Cook, S. L.; Falchi, L.; Frank, A. K.; Gupta, S.; more...
    Cancer Cytopathology (2023)

    Fulltext@MSK | Save
  • Editorial: Advances in the understanding and treatment of cutaneous lymphoma
    Editorial

    Bernardelli, A.; Falchi, L.; Qiao, J.; Visco, C.
    Frontiers in Oncology (2023)

    Fulltext@MSK | Save
  • Outcomes of patients with positive interim positron emission tomography (PET) continuing ABVD in the clinical setting
    Journal Article

    Zheng, S.; Gupta, K.; Goyal, P.; Nakajima, R.; Michaud, L.; Batlevi, C. L.; Hamlin, P. A.; Horwitz, S.; Kumar, A.; Matasar, M. J.; more...
    Cancers (2023)

    Fulltext@MSK | Save
  • Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era
    Research Letter

    Qualls, D.; Imber, B. S.; Okwali, M.; Hamlin, P. A.; Kumar, A.; Lahoud, O. B.; Matasar, M. J.; Noy, A.; Owens, C.; Zelenetz, A. D.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns, and opportunities
    Review

    Falchi, L.; Vardhana, S. A.; Salles, G. A.
    Blood (2023)

    Fulltext@MSK | Save